Is PT-141 Legit? Evidence Grade and Plain-English Verdict
PT-141 is rated Level A. The short verdict: PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point.
Direct Answer
PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Sexual Health
- Best for
- Hypoactive sexual desire disorder (women), sexual dysfunction research, melanocortin pathway
Why the Claim Is Strong or Weak
PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It works through the central nervous system rather than the vascular system.
The evidence file contains 2 cited studies and 3 tracked outcome areas.
Top Evidence Signals
- Female Sexual Desire: Level A, includes human evidence - FDA-approved based on Phase 3 trials showing statistically significant increase in sexual desire and reduction in distress related to low sexual desire in premenopausal women.
- Male Erectile Function: Level B, includes human evidence - Clinical trials demonstrated efficacy in male erectile dysfunction, including cases non-responsive to PDE5 inhibitors. Not FDA-approved for this indication.
- Nausea: Level A, includes human evidence - Nausea is the most common side effect, affecting ~40% of users. Usually mild to moderate and transient.
Where Claims Usually Overreach
- Contraindicated in uncontrolled hypertension
- May cause transient BP increase
- Limit to 8 doses per month
- Risk of hyperpigmentation with frequent use
- Nausea may be significant
Primary Sources
- Bremelanotide for Female Sexual Dysfunction (RECONNECT Phase 3). Obstet Gynecol, 2019.
- Bremelanotide for male sexual dysfunction. Int J Impot Res, 2006.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Female Sexual Desire (Level A), Nausea (Level A), and Male Erectile Function (Level B) |
| Primary citation count | 2 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "Is PT-141 Legit? Evidence Grade and Plain-English Verdict." Last reviewed 2026-06-02. https://examinepeptides.com/answers/is-pt-141-legit/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.